Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]

Detalles Bibliográficos
Autores principales: Pandit, Anuja, Bhalani, Nirav, Bhushan, B.L. Shashi, Koradia, Parshottam, Gargiya, Shweta, Bhomia, Vinay, Kansagra, Kevinkumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021
Materias:
Corrigendum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236353/
https://www.ncbi.nlm.nih.gov/pubmed/34193375
http://dx.doi.org/10.1016/j.ijid.2021.06.030
_version_ 1783714519364665344
author Pandit, Anuja
Bhalani, Nirav
Bhushan, B.L. Shashi
Koradia, Parshottam
Gargiya, Shweta
Bhomia, Vinay
Kansagra, Kevinkumar
author_facet Pandit, Anuja
Bhalani, Nirav
Bhushan, B.L. Shashi
Koradia, Parshottam
Gargiya, Shweta
Bhomia, Vinay
Kansagra, Kevinkumar
author_sort Pandit, Anuja
collection PubMed
description
format Online
Article
Text
id pubmed-8236353
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-82363532021-06-28 Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521] Pandit, Anuja Bhalani, Nirav Bhushan, B.L. Shashi Koradia, Parshottam Gargiya, Shweta Bhomia, Vinay Kansagra, Kevinkumar Int J Infect Dis Corrigendum The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2021-08 2021-06-28 /pmc/articles/PMC8236353/ /pubmed/34193375 http://dx.doi.org/10.1016/j.ijid.2021.06.030 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Corrigendum
Pandit, Anuja
Bhalani, Nirav
Bhushan, B.L. Shashi
Koradia, Parshottam
Gargiya, Shweta
Bhomia, Vinay
Kansagra, Kevinkumar
Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title_full Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title_fullStr Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title_full_unstemmed Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title_short Corrigendum to “Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study” [International Journal of Infectious Diseases, Volume 105, April 2021, Pages 516-521]
title_sort corrigendum to “efficacy and safety of pegylated interferon alfa-2b in moderate covid-19: a phase ii, randomized, controlled, open-label study” [international journal of infectious diseases, volume 105, april 2021, pages 516-521]
topic Corrigendum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8236353/
https://www.ncbi.nlm.nih.gov/pubmed/34193375
http://dx.doi.org/10.1016/j.ijid.2021.06.030
work_keys_str_mv AT panditanuja corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT bhalaninirav corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT bhushanblshashi corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT koradiaparshottam corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT gargiyashweta corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT bhomiavinay corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521
AT kansagrakevinkumar corrigendumtoefficacyandsafetyofpegylatedinterferonalfa2binmoderatecovid19aphaseiirandomizedcontrolledopenlabelstudyinternationaljournalofinfectiousdiseasesvolume105april2021pages516521

Ejemplares similares